Pharmaceuticals, Biotechnology and Life Sciences
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a…
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”),…
Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of…
SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in the discovery of inhibitors of challenging targets…
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in…
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article…
Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) — Faraday…
Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid…
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December…
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company…